CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6897 result(s)

Non-Pharmacological Interventions for Chronic Non-Cancer Pain: Physical Activity

Event Date: September 23, 2020
Result type: Events

Because of the prevalence and burden of chronic pain, health care providers are in search of the best multifaceted approach for treatment knowing that relying on opioids alone can be ineffective and carries substantial risks. Join CADTH for a webinar on the current evidence on physical activity for chronic, non-cancer pain. The target audience f...

Consultation on Drug Reviews: Webinar for Patient Groups

Event Date: July 9, 2020
Result type: Events

Patient groups and other stakeholders are invited to comment on a revised procedure for CADTH’s drug reimbursement review processes (that is, the pan-Canadian Oncology Drug Review, the Common Drug Review, and the Interim Plasma Protein Product Review).  To help patient groups and patients contribute to the consultation, this webinar will h...

emicizumab (Hemlibra)

Last Updated: July 1, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: emicizumab
Indications: Bleeding prevention, hemophilia A

  • Brand Name: Hemlibra
  • Manufacturer: Hoffmann-La Roche Ltd.
  • Project Number: ST0651-000
  • Project Status: Received
  • Submission Type: New

Halobetasol propionate and tazarotene (Duobrii)

Last Updated: June 30, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: Halobetasol propionate and tazarotene
Indications: Psoriasis, moderate to severe plaque

  • Brand Name: Duobrii
  • Manufacturer: Bausch Health, Canada Inc.
  • Project Number: SR0638-000
  • Project Status: Active
  • Submission Type: New

caplacizumab (Cablivi)

Last Updated: June 30, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: caplacizumab
Indications: Acquired thrombotic thrombocytopenic purpura (aTTP)

  • Brand Name: Cablivi
  • Manufacturer: Sanofi-Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0633-000
  • Project Status: Active
  • Submission Type: New

siponimod (Mayzent)

Last Updated: June 29, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: siponimod
Indications: Secondary progressive multiple sclerosis

  • Brand Name: Mayzent
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0631-000
  • Project Status: Active
  • Submission Type: New

Hybrid Closed-Loop Insulin Delivery Systems for People with Type 1 Diabetes

Last Updated: July 2, 2020
Result type: Reports
Product Line: Optimal Use

Hybrid closed-loop insulin delivery systems (HCLs) are a new technology for the management of type 1 diabetes. HCLs combine an insulin pump with a continuous glucose monitor (CGM) and a computer program. Together, these use information from the CGM to automatically determine insulin needs throughout the day and keep the user within a pre-determi...

  • Project Number: OP0548-000
  • Project Status: Active

Tuberculosis

Last Updated: July 2, 2020
Result type: Reports

Tuberculosis (TB) is a highly infectious disease caused by bacteria that spread easily in the air (e.g., through coughing and sneezing). TB usually infects the lungs but can also affect other parts of the body, such as the lymph nodes, urinary tract, and bones. While the overall number of TB cases in Canada is low, there are significant disparit...

  • Project Number: HT0033-000

Evidence Related to Tuberculosis

Last Updated: July 2, 2020
Result type: Resources

Tuberculosis (TB) is a highly infectious disease caused by bacteria that spread easily in the air (e.g., through coughing and sneezing). TB usually infects the lungs but can also affect other parts of the body, such as the lymph nodes, urinary tract, and bones. While the overall number of TB cases in Canada is low, there are significant disparit...